-
Most Popular
Search Results
240 results for dgse
Memo to Bill Gross: The U.S. Is Not Greece
Once again, Pimco’s boss offers a big dose of unhelpful opinion, and his lumping the U.S. in with Greece and Spain is just plain wrong.
Novavax Stock Is Alluringly Attractive at This Stage
Novavax is close to securing FDA approval for its Covid-19 vaccine yet NVAX stock is down since the end of January. What gives?
Covid-19 Vaccine Dose Delay Spells Even More Trouble for Novavax Stock
Investors might hope that the spread of the Delta variant will boost NVAX stock, but a recent news release is likely to hinder progress.
5 Stocks With Weak Free Cash Flow — RGSE I CCCL CMLS RLJE
This week, these five stocks have the worst ratings in Free Cash Flow, one of the eight Fundamental Categories on Portfolio Grader.
5 Stocks With Ugly Free Cash Flow — GBSN I HTZ RGSE CCCL
This week, these five stocks have the worst ratings in Free Cash Flow, one of the eight Fundamental Categories on Portfolio Grader.
5 Stocks With Poor Free Cash Flow — I CCCL RGSE CMLS RLJE
This week, these five stocks have the worst ratings in Free Cash Flow, one of the eight Fundamental Categories on Portfolio Grader.
5 Stocks With Poor Free Cash Flow — CETC RGSE I CCCL CMLS
This week, these five stocks have the worst ratings in Free Cash Flow, one of the eight Fundamental Categories on Portfolio Grader.
Biogen (BIIB): Why Aducanumab Excitement Might Be Overblown
Biogen Inc (BIIB) recently shot up after reporting positive results from aducanumab’s phase 1b study. However, there are some important takeaways from the report that…
After Patent News, Aurinia Pharmaceuticals Still Has More to Prove
Is Aurinia’s patent news a big deal or a modest advance? Here’s why investors have mixed feelings about AUPH stock.
Why Is Novavax (NVAX) Up 30% Today?
While Novavax secured an agreement with the Canadian government over unused Covid-19 vaccines, NVAX stock remains risky.
Why Geron Corporation (GERN), Polaris Industries Inc. (PII) and VimpelCom Ltd (ADR) (VIP) Are 3 of Today’s Worst Stocks
Polaris (PII), VimpelCom (VIP) and Geron (GERN) were conspicuously left out of Monday’s rebound rally. Here’s what you need to know.
Novavax Looks Like a Winner With Its Vaccine Results
Novavax looks like a winner with its positive Covid-19 vaccine results. NVAX stock is worth at least 35% more than today based on widespread acceptance…
Avoid Novavax for Now, Until the Picture Clears Up
NVAX stock may have seen a near-term bounce following the completion of filing of EUA filing with the FDA, but it may not be a…
Why Is Stoke Therapeutics (STOK) Stock Up 99% Today?
Stoke Therapeutics stock is up on Tuesday as STOK shares see heavy trading alongside recent positive clinical trial data.
Why I’m Done With Novavax Stock
Management is terrible at delivering on its promises and even good news has failed to translate into higher prices for NVAX stock.
Ocugen Stock: The Two What-If Scenarios To Consider
OCGN stock is now facing an all or nothing business development and is at a very critical stage so it is wise to avoid it.
Covid Vaccine Update: How Do the Moderna and Pfizer Coronavirus Vaccines Compare?
With a new Covid vaccine update today, how do the Moderna and Pfizer coronavirus vaccines compare? Dive in here.
NVAX Stock Alert: The Covid-19 Vaccine News Sending Novavax Higher Today
News that Australia has received its first shipment of Novavax’s Covid-19 vaccine has NVAX stock taking off nearly 9% in today’s trading.
Why Is Akero Therapeutics (AKRO) Stock Down 58% Today?
Akero Therapeutics (stock is falling hard on Tuesday after the company failed to impress AKRO investors with its clinical trial results.
Why Is BioXcel Therapeutics (BTAI) Stock Down 57% Today?
BioXcel Therapeutics (BTAI) stock is taking a beating on Thursday after the company released its latest clinical trial data.
Trade of the Day: Micron Technology (MU)
A healthy dose of caution is always appropriate, which is why I continue to recommend short-term covered calls with a mix of long-term dividend names.
5 ETFs to Play Apple’s Big Rally
These five funds give you a big, low-cost dose of Apple stock exposure while also offering diversification across a number of other positions.
5 – 10 of 240 results
